Women and lung cancer: Epidemiology, tumor biology, and emerging trends in clinical research

被引:79
作者
Belani, Chandra P.
Marts, Sherry
Schiller, Joan
Socinski, Mark A.
机构
[1] Soc Womens Hlth Res, Washington, DC 20036 USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[3] Univ Texas, SW Med Sch, Simmons Comprehens Canc Ctr, Dallas, TX 75230 USA
[4] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
关键词
lung neoplasms; female; biomedical research; therapy;
D O I
10.1016/j.lungcan.2006.09.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is the leading cause of cancer-related death in both men and women. Environmental carcinogens, particularly tobacco smoke, play a dominant rote in the development of lung cancer, although 10-15% of all patients diagnosed are non-smokers. In addition, emerging data demonstrate sex-specific differences in lung cancer susceptibility and prognosis. This implies that the development of lung cancer is modulated by complex interactions between genetic, hormonal, behavioral, and environmental factors. A better understanding of the differences between men and women and their impact on the prevention, diagnosis, and treatment of lung cancer requires continued basic and clinical research. Recent data on the epidemiological aspects of lung cancer in women, lung tumor biology, and emerging trends in clinical research were presented at a thought leaders' roundtable hosted by the Society for Women's Health Research. The panel concluded that as the patient population in lung cancer is changing from mostly mate smokers to include women and non-smokers, an urgent need exists to increase awareness and research funding to improve Lung cancer care, particularly in women. To further improve survival in this disease, both clinical characteristics and tumor biology should be considered in the development of new treatment options. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:15 / 23
页数:9
相关论文
共 99 条
[1]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[2]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[3]   Sex and racial differences in pharmacological response: Where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics [J].
Anderson, GD .
JOURNAL OF WOMENS HEALTH, 2005, 14 (01) :19-29
[4]  
Anderson Robert N, 2003, Natl Vital Stat Rep, V51, P1
[5]   The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer:: a study of absolute and relative survival over 15 years [J].
Båtevik, R ;
Grong, K ;
Segadal, L ;
Stangeland, L .
LUNG CANCER, 2005, 47 (02) :173-181
[6]   Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials [J].
Bell, DW ;
Lynch, TJ ;
Haserlat, SM ;
Harris, PL ;
Okimoto, RA ;
Brannigan, BW ;
Sgroi, DC ;
Muir, B ;
Riemenschneider, MJ ;
Iacona, RB ;
Krebs, AD ;
Johnson, DH ;
Giaccone, G ;
Herbst, RS ;
Manegold, C ;
Fukuoka, M ;
Kris, MG ;
Baselga, J ;
Ochs, JS ;
Haber, DA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8081-8092
[7]  
Brahmer JR, 2006, J CLIN ONCOL, V24, p373S
[8]   Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation [J].
Bunone, G ;
Briand, PA ;
Miksicek, RJ ;
Picard, D .
EMBO JOURNAL, 1996, 15 (09) :2174-2183
[9]   Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma [J].
Chen, KY ;
Chang, CH ;
Yu, CJ ;
Kuo, SH ;
Yang, PC .
CANCER, 2005, 103 (12) :2566-2574
[10]   Malignant melanoma [J].
de Braud, F ;
Khayat, D ;
Kroon, BBR ;
Valdagni, R ;
Bruzzi, P ;
Cascinelli, N .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 47 (01) :35-63